When Novartis unveiled a plan in 2018 to grant its Sandoz generics business more autonomy, industry watchers read spinoff. Now, a separation may be around the corner. Novartis has launched a strategic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results